WO2000074489A1 - Stable biocidal compositions - Google Patents
Stable biocidal compositions Download PDFInfo
- Publication number
- WO2000074489A1 WO2000074489A1 PCT/NZ2000/000087 NZ0000087W WO0074489A1 WO 2000074489 A1 WO2000074489 A1 WO 2000074489A1 NZ 0000087 W NZ0000087 W NZ 0000087W WO 0074489 A1 WO0074489 A1 WO 0074489A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phase
- active
- composition
- organic
- anthelmintic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Definitions
- the present invention relates to pesticidal compositions, their preparation and their use.
- the present invention relates to multiple active ingredient liquid formulations of a kind where for stability pu ⁇ oses different environments are required for at least two of the active ingredients. For instance, when in an aqueous phase pH requirements for stability differ significantly, eg; a low pH is required for levamisole and a neutral pH is required for abamectin, a macrocyclic lactone (ML) (see Table 2 hereafter). Also of the common anthelmmtics, levamisole salts are usually much more soluble than morantel salts in aqueous systems, M.L anthelmintics are generally more soluble in organic systems than aqueous systems and benzimidazoles are sparingly soluble.
- pH requirements for stability differ significantly, eg; a low pH is required for levamisole and a neutral pH is required for abamectin, a macrocyclic lactone (ML) (see Table 2 hereafter).
- levamisole salts are usually much more soluble than morantel salts in aqueous systems
- a particular (but not only) area of interest in stable formulation are those formulations of biocides useful in controlling helminths including nematodes, cestodes, trematodes, and/or ectoparasites.
- the mode of administration including oral, mjectable or pour-on
- LUVITAPETM paraffin oil
- Merck NZ 183847 discloses avermectin anthelmintic compounds for parenteral administration where they may be carried by a vegetable oil such as peanut oil, cotton seed oil and the like.
- Sankyo NZ 199817 refers to oral formulations of two or more anthelmintics where one is a macrolide (or ML) anthelmintic and another may be, for example, a benzimidazole (eg; albendazole), a salicylamide (eg; niclosamide) or an isoquinoline compound (eg; praziquantel).
- a benzimidazole eg; albendazole
- salicylamide eg; niclosamide
- an isoquinoline compound eg; praziquantel
- Such formulations are not exemplified by any storage stable formulation although reference is made to formulation as an aqueous solution, as a solution in another suitable non-toxic solvent or as a suspension or dispersion inco ⁇ orating a suspension aid and a wetting agent (eg; bentonite) or other constituents.
- Doramectin is available from Pfizer as DECTOMAXTM as a parenteral formulation of sesame oil and ethyl oleate.
- Ashmont NZ 280085/280134 discloses injectable ML anthelmintic formulations (eg; abamectin or ivermectin) where a alcohol (such as benzyl alcohol - long since used as a preservative in injectable formulations) acts as a co-solvent with a vegetable oil vehicle (eg; soyabean oil, sesame oil or com oil).
- a vegetable oil vehicle eg. soyabean oil, sesame oil or com oil.
- ethyl oleate is also disclosed.
- Ashmont further discloses (w/w %) a formulation as follows;
- ML anthelmintic active 0.5 to 5% w/w benzyl alcohol 1 to 30% w/w vegetable oil to 100% w/w ethyl oleate zero or 5 to 30% w/w
- the present invention is directed to compositions having at least two actives preferably each usable as an anthelmintic active (albeit with a different spectrum of efficacy with respect to nematodes, trematodes, flukes, etc.) and preferably involving other therapeutic agents.
- the present invention relates to a benzimidazole containing composition (eg; for pour-on use) where the benzimidazole is solubilised in an organic acid containing phase (eg; lactic acid).
- antihelmintic and derivatives thereof shall encompass, where the context allows any one or more of a nematocidal, trematocidal and cestocidal active compounds. Where the context so allows “pesticidal” and derivatives thereof shall include any such anthelmintic and any ectoparasitocidal compound. Where the context allows “ectoparasitocidal” shall include compounds effective against any one or more of ticks, lice, flies, et al.
- stable means at least 3 months (preferably at least 18 months) chemical stability (eg; within plus or minus 10% w / w of its stated composition) of the active ingredients when stored at 25 °C or below and at ambient humidity and of reasonable physical stability such that the composition is substantially homogeneous (despite any option particulate inclusion(s)) and/or can readily be agitated to such condition.
- particle means true particles (ie; parts of solids) as well as liposomes or the equivalent optionally which may be or carry an active ingredient.
- particles are almost exclusively less than lOO ⁇ (microns).
- the better eg; preferably substantially all less than 50 ⁇ , more preferably less than 30 ⁇ , still more preferably than 20 and even more preferably less than ⁇ 0 ⁇ ).
- solubility refers to the ability of a compound to be dissolved in a specific phase.
- lipophilic means a greater tendency to an orangic, oil or the like phase as opposed to the other phase (preferably aqueous).
- pourable or “flowable” in respect of a fluid or liquid covers viscosities ranging from a free flowing liquid to a gel or paste consistency that is able to be expelled by syringe, drench or paste gun.
- pourable is irrespective of whether it is to be used as a pour on or otherwise.
- the invention consists in a pesticidal composition comprising or including
- said pesticidal composition (or indeed any biocidal composition) disclosed herein is a veterinary composition.
- the lipophilic active ingredient is chosen from the class of macro cyclic lactones (hereafter "ML").
- a particulate content there is present in said aqueous phase a particulate content.
- said aqueous phase has a pH of less than 6 (more preferably less than 5 and most preferably 4 or below).
- said aqueous phase includes a buffering system to buffer the pH to preferably a pH suitable for the levamisole.
- said buffering system is a citric acid/citrate salt system.
- said at least one organic liquid carrier is an oil (e.g. vegetable or mineral, or mixtures thereof).
- said organic liquid phase includes a co-solvent.
- co-solvent is benzyl alcohol.
- said aqueous phase includes a particulate content of either an active agent or an inert substance.
- the particulate active agent is a biocide.
- composition includes in one or other, or both, of the partitioned phases one or more of the group comprising minerals and vitamins.
- the invention is an anthelmintic composition having about 0.08% ivermectin, about 3% levamisole, and about 2% albendazole where different liquid carrier phases substantially partition the ivermectin from the levamisole, and where the albendazole is particulate and is at least in part in an aqueous phase with the levamisole, such aqueous phase being buffered to a pH appropriate for the levamisole and its stability.
- the present invention consists in a storage stable pourable pesticidal composition having an organic first liquid phase and another (“second") liquid phase, said first phase including at least one active ingredient (and optionally a co-solvent for said active ingredient) and said second phase including a second active ingredient whereinthe presence of an emulsifying agent and/or anti-flocculants ensures stability of the two phases with the first phase with its first active ingredient as an emulsion within said second phase with its second active ingredient.
- said second phase is an organic acid and/or aqueous phase.
- said second phase comprises or includes an organic acid such as lactic acid.
- said first phase comprises an oil and/or emollient ester.
- said active ingredients in each of said phases or which might be present as an additional active in both or either phase comprises any of the examples hereinafter provided.
- the invention consists in a stable mix of two or more immiscible liquids or liquid phases held together by an emulsifier or emulsifiers where one phase is an organic water immiscible phase and another phase is an aqueous or organic phase (eg; water or organic acid(s) such as lactic acid).
- an emulsifier or emulsifiers where one phase is an organic water immiscible phase and another phase is an aqueous or organic phase (eg; water or organic acid(s) such as lactic acid).
- the present invention consists in a benzimidazole composition comprising an organic acid (such as lactic acid) and the benzimidazole dissolved therein.
- the present invention consists in a topical or pour-on benzimidazole composition where the benzimidazole is solubilised in an organic acid (such as lactic acid).
- the present invention consists in a benzimidazole containing composition where at least one phase is that of an organic acid (such as lactic acid) which solubilises at least one benzimidazole active ingredient.
- an organic acid such as lactic acid
- the invention consists in a ready to use pesticidal veterinary liquid composition of at least a first active in a first liquid phase and at least a second active in a second liquid phase, the phases forming a stable emulsion.
- a third active may be present in one or other or both of said phases.
- Such third active may be suspended in at least one phase.
- each of said first and second actives are dissolved (at least in part) in their respective phases.
- the present invention consists in a preferably storage stable pourable composition comprising or including up to 25% w/v of at least one pesticide (hereafter "first active(s)”) soluble in an organic phase,
- first liquid phase in which said first active(s) is (are) at least substantially soluble
- second active(s) not substantially soluble in said first phase
- second active(s) means providing a second liquid phase, said composition having at least most of said first active(s) in a first phase and said first phase being emulsified in the second phase which includes said second active(s).
- the present invention consists in a preferably storage stable composition (whether as a concentrate for aqueous dilution or otherwise) comprising or including up to 25%o w/v of at least one pesticide (hereafter "first active(s)”) chosen from the class of at least partly oil or emollient ester soluble actives, 1 to 60%) w/v of at least one water immiscible organic phase [such as a oil (vegetable or mineral) and/or emollient esters] in which said first active(s) is (are) at least substantially soluble,
- first active(s) chosen from the class of at least partly oil or emollient ester soluble actives, 1 to 60%
- water immiscible organic phase such as a oil (vegetable or mineral) and/or emollient esters
- second active(s) not substantially soluble in said organic phase which is (i) dissolved in said water and/or (ii) suspended in said water, and, water, said composition having an organic phase with at least most of said first active(s), said organic phase being emulsified in an aqueous phase of said water and said second active(s).
- said first and second active are anthelmintics.
- said organic phase at least includes an oil.
- additional active ingredients are included in said composition whether in said organic phase or said aqueous phase or a mixture of them both.
- an additional active ingredient may be included in such a way that the composition is a suspo-emulsion.
- the present invention consists in a storage stable pesticidal composition having an organic phase and an aqueous phase, said organic phase being of an oil and/or emollient ester which includes at least one active ingredient (and optionally a co- solvent for said active ingredient) and an aqueous phase including a second active ingredient which is substantially insoluble in said organic phase wherein the presence of an emulsifying agent and/or anti-flocculants ensures stability of the two phases with the organic phase as an emulsion within said aqueous phase.
- said composition includes still further actives which as particles, liposomes or as liquid globules are suspended in one or other or both of said phases.
- said first active may be a broad spectrum anthelmintic such as an ML anthelmintic (eg; abamectin) and said second active is a water soluble active also capable of killing nematodes such as levamisole.
- An additional active or additional actives may include one or more of suitable actives dissolvable or suspendible or emulsifiable in one or other of the phases having, for example, an additional anthelmintic, or an active with an ectoparasitocidal effect or a flukicidal effect. Equally this may contain two or more actives that have activity against trematodes such as Flukes or Cestodes, or Ectoparasites.
- the present invention consists in a pourable pesticidal composition
- a pourable pesticidal composition comprising or including at least one active ingredient chosen from the class of macro cyclic lactones (hereafter
- ML ML
- active ingredient chosen from the tetramisole/levamisole class
- organic liquid carrier preferably at least one oil and, optionally, at least one organic co-solvent
- emulsifying agent or agents preferably at least one oil and, optionally, at least one organic co-solvent
- said ML active ingredient(s) is(are) at least primarily in the first phase in solution
- said tetramisole/levamisole class active ingredient(s) is(are) at least primarily in solution in the second phase
- said phases exist in, or can be shaken or agitated into, the form of an emulsion.
- the present invention consists in a pesticidal composition (whether as a concentrate for aqueous dilution or otherwise) comprising or including at least one active ingredient chosen from the class of macro cyclic lactones (hereafter
- ML ML
- active ingredient chosen from the tetramisole/levamisole class
- organic liquid carrier preferably at least one oil and, optionally, at least one organic co-solvent
- water preferably at least one oil and, optionally, at least one organic co-solvent
- an emulsifying agent or agents wherein said ML active ingredient(s) is(are) at least primarily in the organic liquid carrier(s) in solution (hereafter referred to as "the organic phase")
- said tetramisole/levamisole class active ingredient(s) is(are) at least primarily in solution in the water (hereafter refe ⁇ ed to as "the aqueous phase")
- said organic phase and said aqueous phase exist in, or can be shaken into, the form of an emulsion.
- a co-solvent is present.
- co-solvent is selected from the class of alcohols having multiple carbons (preferably 4 or more) (eg; benzyl alcohol), diols and
- a third active ingredient is included in the composition.
- said third ingredient if an anthelmintic is other than an ML anthelmintic and other than an anthelmintic chosen from the tetramisole/levamisole class.
- said third anthelmintic agent is selected from the group including benzimidazoles and probenzimidazoles (eg; albendazole, oxfendazole, triclabendazole), praziquantel, salicylamides (eg; closantel), organophosphates, (napthalophos), clorsulon, nitroxynil, morantel, pyrantel, et al. - see Table 2 - Spectrum of Activity.
- said third anthelmintic active ingredient is suspended at least primarily in the aqueous phase.
- said aqueous phase includes at least one suspension agent for said third anthelmintic active ingredient.
- the present invention consists in a (preferably storage stable) pourable composition comprising or including at least one anthelmintic active (hereafter "first anthelmintic active(s)”), at least one liquid to provide a first phase in which said first anthelmintic active(s) is (are) at least substantially soluble, an emulsifying agent, at least one liquid to provide a second phase, and at least one further anthelmintic active (hereafter "second anthelmintic active(s)”) not substantially soluble in said first phase, said composition having a first phase with at least most of said first anthelmintic active(s) and a second phase of at least most of said second anthelmintic active(s).
- the present invention consists in a (preferably storage stable) composition (whether as a concentrate for aqueous dilution or otherwise) comprising or including at least one anthelmintic (hereafter “first anthelmintic active(s)”) chosen from the class of at least partly oil soluble anthelmintic actives, at least one oil (optionally also with an organic co-solvent) in which said first anthelmintic active(s) is (are) at least substantially soluble, an emulsifying agent, water, and at least one further anthelmintic active (hereafter “second anthelmintic active(s)”) not substantially soluble in said oil(s) which is (i) dissolved in said water and/or (ii) suspended in said water, said composition having an organic phase of said oil(s) with at least most of said first anthelmintic active(s) and an aqueous phase of said water and at least most of said second anthelmintic active(s).
- first anthelmintic active(s) chosen
- said oil is a vegetable oil or a mineral oil.
- said composition includes a third active.
- said third active is a therapeutic agent such as an antimicrobial and/or still further anthelmintic active (eg; flukicide) and/or an ectoparasitocide (hereinafter "third active(s)").
- said third active(s) is primarily disposed within said aqueous phase although in other forms of the present invention it may be partitioned between the organic and aqueous phases or largely in the organic phase.
- said second anthelmintic active(s) is dispersed substantially homogeneously as a suspension in the water.
- composition includes any one or more of the following:
- a co-solvent which is to form part of said aqueous phase, eg; as maybe preferable if the first anthelmintic active(s) is only partially soluble in the vegetable oil(s),
- said vegetable oil(s) is selected from the group including soyabean oil, sesame seed oil, com oil, sunflower oil, peanut oil and safflower oil.
- said emulsifying agent is Tween 80 and/or Teric 380.
- said second anthelmintic active is selected from the group consisting of levamisole or tetramisole (if a water phase soluble anthelmintic) or a water phase suspendible or dispersible anthelmintic such as a suitable benzimidazole typified by, for example, albendazole or oxfendazole.
- said optional third active is a dispersed benzimidazole.
- said cosolvent is selected from the group including high chain alcohols (such as benzyl alcohol), diols, glycol ethers, and esters (eg; PMP).
- high chain alcohols such as benzyl alcohol
- diols such as diols
- glycol ethers such as glycol ethers
- esters eg; PMP
- said antimicrobial is selected from the group including benzoic acid, potassium sorbate and parabens.
- said minerals are selected from the group including mineral salts or chelates, eg; selenium, copper, cobalt, iodine and zinc.
- said vitamins are selected from the group including vitamins A, D, E, B and
- antifreeze or freezes is or are selected from the group consisting of propylene glycol and glycerine.
- said thickening agent are selected from the group of cellulose gum, xanthan gum, carbapol and algeinates.
- anti-flocculants are selected from the group consisting of Terasperse 2500 and 4896 (preferably both).
- pH stabilisers are selected from the group consisting of citric acid, phosphate salts, etc.
- organic liquid carrier is an oil.
- said oil is a vegetable oil.
- said oil is a mineral oil (eg; medium grade).
- said vegetable oil is selected from a group consisting of or including soyabean oil, com oil, sesame seed oil, sunflower oil, peanut oil and safflower oil.
- the present invention is a stable formulation of a first active in an organic ("first") phase, a second active in a second liquid phase, and additional actives in one or other, or both, said phase(s), and wherein said phases provide a stable emulsion, and wherein at least one (and preferably both) of said first and second actives is (are) an anthelmintic active.
- a third active is a suspended active at least primarily in the second phase (eg; an anthelmintic or ectoparasiticide).
- an emulsifying agent assists in the stability of the emulsion.
- the present invention is a stable formulation of a first active in an organic phase at least primarily of oil(s), a second active in an aqueous phase, and additional actives in one or other, or both, said organic and aqueous phase(s), and wherein said organic and aqueous phases provide a stable emulsion, and wherein at least one (and preferably both) of said first and second actives is (are) an anthelmintic active.
- a third active is a suspended active at least primarily in the aqueous phase (eg; an anthelmintic or ectoparasiticide).
- an emulsifying agent assists in the stability of the emulsion.
- the invention consists in a storage stable and pourable pesticidal composition comprising or including
- phase (b) a particulate content, and wherein said phases exist in, or can be shaken or agitated into, the form of an emulsion with said particulate content, if any, at least substantially present in the aqueous phase.
- the invention is an anthelmintic oil in water emulsion carrying at least one macro cyclic lactone (ML) in the oil phase and particles of levamisole and an emulsifying agent for the levamisole in the aqueous phase.
- ML macro cyclic lactone
- the invention is a partitioned biocidal composition
- a partitioned biocidal composition comprising in an organic phase a first biocide, and in an aqueous phase at acid pH a second biocide, said first biocide being unstable chemically at said acid pH.
- said composition has particles suspended in at least the aqueous phase.
- said particles are themselves biocidal.
- said particles are of a benzimidazole anthelmintic.
- the invention consists in a method of formulating an anthelmintic composition of a kind having at least one anthelmintic (hereafter "first active(s)”), a liquid or liquids to define a first phase in which said first active(s) is (are) at least substantially soluble,
- second active(s) At least one further anthelmintic active not substantially soluble in said first phase
- the invention consists in a method of formulating an anthelmintic composition of a kind having at least one anthelmintic (hereafter "first active(s)”) chosen from the class of (at least partly) oil soluble anthelmintic actives, an oil or oils in which said first active(s) is (are) at least substantially soluble, optionally a cosolvent for said first active(s), an emulsifying agent, at least one further anthelmintic active (hereafter "second active(s)”) not substantially soluble in said oil(s), optional anti-flocculant(s), and, water, said method comprising or including the steps of
- the invention consists in an anthelmintic composition so made.
- the invention is a method of treating mammals for pests which involves (whether with dilution or not) administering or having self administered to such mammals effective amounts of active(s) of compositions of the present invention.
- the invention consists in the use of an anthelmintic composition of any of the kinds previously defined.
- said use is as an oral, a pour-on or as a parenteral composition (preferably with an anthelminticly effective amount of each active).
- Preferred formulations of the present invention comprise:
- Component 1 water insoluble but mostly or completely oil soluble anthelmintic active.
- Component 2 An oil (vegetable or mineral)
- Component 3 an emulsifying agent
- This or these can be either dissolved in the water phase (such as Levamisole) or suspended in the water phase (such as Albendazole) if insoluble, or both (eg; Levamisole and Albendazole).
- the water insoluble active is dissolved in the oil, which is emulsified in water.
- the oil protects the active against the pH or constituents present in the water phase. Additional components can be added to this basic formulation. Addition 1 - if component 1 is only partially soluble in the oil phase then a co-solvent may be necessary (eg; an organic co-solvent).
- Addition 2 Minerals/Vitamins Addition 3 - An antimicrobial. Addition 4 - Antifreezes. Addition 5 - Thickening agents.
- Figure 1 is a plot from the cattle trial NCOOl hereafter referred to of Avermectin
- Figure 2 is a plot of Levamisole blood levels ( ⁇ g/ml) against time (hours) for the different modes of administration in cattle,
- Figure 3 is a plot of Oxfendazole blood levels ( ⁇ g/ml) against time (hours) for the different modes of administration in cattle,
- Figure 4 is a plot of Fenbendazole blood levels ( ⁇ g/ml) against time (hours) for the different modes of administration in cattle,
- Figure 5 is a plot of Avermectin Bla blood level (ng/mL) against time (hours) for the oral combination against a commercial oral formulation in sheep,
- Figure 6 is a plot of Levamisole blood level ( ⁇ g/ml) against time (hours) for the oral combination against a commercial oral formulation in sheep,
- Figure 7 is a plot of Albendazole blood levels ( ⁇ g/ml) against time (hours) for the oral combination against a commercial oral formulation in sheep,
- Figures 8 to 10 are stability graphs for each of Abamectin, Levamisole and
- Figure 11 is a plot of Levamisole content against Time for formulation LB98/92
- Figure 12 is a plot of pH against Time for formulation LB98/92
- Figure 13 shows stability results and graphs for formulation LB99/01 of Table 7
- Figure 14 shows stability results and graphs for formulation LB99/02 of Table 8
- Figure 15 shows stability results and graphs for formulation LB99/03 of Table 9
- Figure 16 stability graphs of pH changes with time for formulations LB99/54A
- Figure 17 shows (for a 50°C accelerated stability trial) the change of pH of formulations/drenches of Tables 12 and 13 with time
- Figure 18 shows (for a 50°C accelerated stability trial) the change of viscosity (cp) of formulations/drenches of Tables 12 and 13 with time
- Figure 19 shows (for a 50°C accelerated stability trial) the change of mean droplet/particle size of formulations/drenches of Tables 12 and 13 with time.
- Figure 20 shows (for a 50°C accelerated stability trial) the change of moisture content of formulations/drenches of Tables 12 and 13 with time
- Figure 21 shows (for a 50°C accelerated stability trial) the change of levamisole content of formulations/drenches of Tables 12 and 13 with time
- Figure 22 shows (for a 50°C accelerated stability trial) the change of praziquantel content of formulations/drenches of Tables 12 and 13 with time
- Figure 23 shows (for a 50°C accelerated stability trial) the change of albendazole content of formulations/drenches of Tables 12 and 13 with time
- Figure 24 shows (for a 50°C accelerated stability trial) the change of ivermectin content of formulations/drenches of Tables 12 and 13 with time
- Figure 25 shows (for a 50°C accelerated stability trial) the change of abamectin content of formulation/drenches of Tables 12 and 13 with time
- Figure 26 shows (for a 50°C accelerated stability trial) the change of benzyl alcohol content of formulations/drenches of Tables 12 and 13 with time
- Figure 27 shows (for a 50°C accelerated stability trial) the change of selenium content of formulations/drenches of Tables 12 and 13 with time
- Figure 28 shows (for a 50°C accelerated stability trial) the change of cobalt content of formulations/drenches of Tables 12 and 13 with time
- Figure 29 shows the positive effect against clumping/aggregation from the presence of particles of Levamisole hydrochloride, the unclumped dish to the right being that (LB99/96C of Table 14) with Levamisole, the others (LB99/96A and LB99/96B of Table 14) having no such presence and clumping
- Figure 30 shows the results of freeze/thaw trials (mLs separation - 200mL samples being cycled between minus 4°C and ambient for 4 days) for formulations/drenches of Table 15, and
- Figure 31 shows a photograph of phase separation(A) after f eeze thawing compared with a stable homogeneous formulation(B) of the invention.
- Citric Acid 0.29 % w/v
- Citric Acid 0.29 % w/v
- Citric Acid 0.29 % w/v
- Citric Acid 0.29 % w/v
- Citric Acid 1.21 % w/v
- Soyabean Oil 3.00 % w/v
- Citric Acid 1.21 % w/v
- Soyabean Oil 3.00 % w/v
- Teric 380 a more appropriate emulsifying agent for stable vegetable oil emulsions.
- the percentage of the oil phase was increased to 10% to increase the partition between the oil/water phase possibly improve Abamectin stability.
- Soyabean Oil 10.0 % w/v
- Soyabean Oil 10.0 % w/v Water 85.0 % w/v
- Soyabean Oil 40.00 % w/v Xanthan gum 0.30 % w/v
- Example 12 Although formulation of Example 12 was showing indications of suitability another formulation option was tested. Xanthan Gum was replaced with Alginate as a alternative thickener.
- Soyabean Oil 40.00 % w/v Xanthan gum 0.30 % w/v
- Soyabean Oil 40.00 % w/v Xanthan gum 0.30 % w/v
- Soyabean Oil 35.00 % w/v
- Citric Acid/Sodium Citrate system which uses Citric acid/sodium hydroxide
- test formulations A, B, C, D, E and J
- 4 commercial formulations consisting of 3 single active drenches (F, G, H) and 1 triple active drench (I) were placed under identical conditions, including identical high density polyethylene containers and identical closure systems and placed in a 50 °C oven at ambient humidity.
- In the test formulations of the invention used either abamectin or ivermectin triple active formulations, with or without minerals, buffered or unbuffered, and one had the addition of praziquantel (E). These are detailed in Table 12 and 13.
- Formulations A, B, C, D, E and J are formulations of the present invention.
- Viscosity decrease was greatest in quad drench E, which started out with the highest initial viscosity (Figure 18). Correlates well with the observed particle size increase (Figure 19).
- the triple formulations of the present invention showed the best stability with respect to viscosity. In the test formulations the particles measured would predominantly be the oil droplets/particles.
- Drench F has a very low viscosity (>100 x less than preferred formulations of the present invention), hence stability related decreases are not expected to be significant
- Drench F IVOMECTM sheep drench
- Drench F has twice the level of benzyl alcohol than the formulations of the present invention and also twice the water content.
- formulations of the present invention show physical and chemical stability that is at least as good as products F, G, H and I available on the New Zealand market
- Formulations were developed with higher loading of actives, substituting and loading particulate content using silicon dioxide and titanium dioxide. These formulations were developed to be used as pour-ons, injectible or as oral gels. The following formulations were prepared.
- Colloidal Silicon Dioxide was added to the formulation as a substitute for the solid component (such as Albendazole, Oxfendazole and Triclabendazole) that might desirably be found in the oral formulations.
- Titanium Dioxide filled a similar function to such benzimidazole solids insofar as stability is concerned as well as an UV screen. Observations:
- Formulation LB99/96C was also considered suitable for an injectable formulation but ideally would have the silicon dioxide/titanium dioxide substituted with a readily biodegradable/metabolised particle and the levamisole hydrochloride substituted by levamisole phosphate to be less irritant at the injection site.
- Formulation LB99/72A formed a white thick pourable gel which was considered to have application for example orally in horses, dogs and cats.
- Test - The pour-on formulations listed in Table 14 (LB99/96A, LB99/96B and LB99/96C) were mixed with 10% extra water and any effect observed.
- Test - Formulations of the present invention (such as LB 99/96A, LB99/96B and LB99/96C of Table 14) were applied though a standard drench gun containing residual water.
- drenches of the present invention when repeatedly frozen and then thawed was investigated.
- a series of Triclabendazole, Abamectin and Levamisole drenches, LB99/52A to LB99/52G were formulated and was cycled between minus 4°C (- 4°C) and ambient conditions daily for 4 days. Their response to these conditions was compared to that of a number of current standard suspension drenches; SYSTAMEXTM, VALBAZENTM and FIRST DRENCHTM.
- LB99/52C is considered a "standard” with 1.0% Terasperse 4896, 2.0% Terasperse
- Drenches of the present invention differ from standard suspension drenches in the way they separate. Standard drenches separate to form a clear layer on top, while drenches of the invention form a similar layer on the bottom. This may be due to density. Suspended solids are usually heavier than water and may sink, while oil-based emulsions, as in drenches of the present invention, are usually lighter than water and may remain in the top portion. In physically unstable formulations of the present invention there is a top phase of oil, a middle phase of suspended solids, and a bottom water layer phase. This is illustrated as A in Figure 31. This contrasts with the physically stable formulation (B of Figure 31) which remained homogeneous.
- the oil within the formulation also acts as lubricant in the drench gun. It is common farming practice to leave drench guns to sit with traditional suspensions within them. Over time there is settling out of particles and a drying out of the product including around the plunger. This can result in the particulate material abrading and damaging the drench gun when reused. In the current invention, the oil keeps the drench gun lubricated, making such damage less likely.
- Animals in group 2 were treated with the test combination formulation orally (Batch LB99/03, see example 15) at a dose of lmL per 5 kg bodyweight.
- Group 3 of four animals had the same product (Batch LB99/03) applied as a pour-on along the midline of the upper back at a dose of 1 mL per 2.5 kg bodyweight.
- Group 4 received the same dose rate of the three actives as in group 2 given orally using three separate commercial formulations.
- Group 1 received no treatment (untreated control animals).
- Figure 1 is a plot of Avermectin Bla blood levels (ng/mL) against time (hours) for the different modes of administration
- Figure 2 is a plot of Levamisole blood levels ( ⁇ g/ml) against time (hours) for the different modes of administration
- Figure 3 is a plot of Oxfendazole blood levels ( ⁇ g/ml) against time (hours) for the different modes of administration.
- Figure 4 is a plot of Fenbendazole blood levels ( ⁇ g/ml) against time (hours) for the different modes of administration.
- the blood profiles in pour-on treated animals shows that levamisole blood levels were similar to those achieved orally, the abamectin were ten times lower than with the commercial oral abamectin formulation and low levels of oxfendazole and fenbendazole (a metabolite) were detected in blood.
- Group 2 received the combination product orally as detailed in example 14
- Faeces for parasite FEC and blood for blood levels of active were collected at various times following treatment (day 0). Animals were slaughtered at day 14 following treatment, with total numbers of worms counted within the gastrointestinal tract.
- Figure 5 is a plot of Avermectin Bla blood level (ng/mL) against time (hours) for the oral combination against a commercial oral formulation
- Figure 6 is a plot of Levamisole blood level ( ⁇ g/ml) against time (hours) for the oral combination against a commercial oral formulation
- Figure 7 is a plot of Albendazole blood levels ( ⁇ g/ml) against time (hours) for the oral combination against a commercial oral formulation.
- treatment A One group (treatment A) remained as untreated controls, the other 4 treatment groups were treated with a pour-on formulation at Day 0 as described in Table 24 using a syringe held 3-5cm above the animal skin with the products applied along the midline of the back between the shoulder blades (withers) in a line approximately 15cm long. This area was chosen to prevent calves licking themselves and they were observed after pour-on treatment to ensure that licking of other calves, particularly the pour-on site, did not occur.
- the 67 lambs were randomly allocated by egg count into 4 groups of 10 lambs (Groups A, B, C, D) and 3 groups of 9 lambs (Groups E, F, G).
- the 3 groups of 9 lambs (E, F G) were drenched with a commercial formulation from one of the three broad spectrum anthelmintic drench families consisting of albendazole, a member of the benzimidazole or white drenches (Group E), levamisole, a member of the imidazothiazole
- Group F / tetrahydropyrimidazole or clear drenches
- Ivermectin a member of the macrocychc lactones
- Group G a member of the macrocychc lactones
- Group A remained as untreated controls
- Group B received the unmineralised test product (formulation 00-27C) containing all 3 actives (albendazole, levamisole, ivermectin)
- Group C received the same basic formulation but with the addition of selenium as the sodium selenate (formulation
- the larvae originated from four New Zealand sheep farms, three of which had evidence of resistance to one or more drench families.
- Lambs were injected with 0.5mL of a corticosteroid (opticortenol) two days prior to artificial oral larval infection. This was done to assist establishment of the worm larvae. 25 days after infection the animals were restrictively allocated to groups by bodyweight and also the presence of tapeworm infection, to one of seven treatment groups (Groups A-G).
- Four treatment groups the untreated control and test products Groups A-
- D) had 8 animals per group, and three groups (E-G) contained 7 animals per group.
- the groups with 7 animals per group (E, F, G) were orally dosed with a single standard commercial product. All animals were slaughtered at Day 7 and Day 8 after treatment and total numbers of gastrointestinal roundworms and tapeworms counted.
- the treatment groups, liveweight and formulation and dose rate data are summarised in Table 29.
- the worm count data, including tapeworm data is summarised in Table 30.
- SUBSTITUE SHEET (Rule 26) Against Nematodirus in the small intestine, ivermectin and the three test products were fully effective (100% reduction), levamisole removed 99% of adult Nematodirus and albendazole removed only 59%.
- Levamisole alone and the combination test formulations were highly effective against all roundworm species in this trial.
- the three test formulations removed more worms than any of the single active commercial formulations alone indicating the benefits of combining the actives together in one single formulation.
- the test formulation with praziquantel was effective in removing the tapeworm Moniezia.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT00931765T ATE313952T1 (en) | 1999-06-04 | 2000-06-02 | STABLE BIOCIDAL COMPOSITION |
AU49595/00A AU772988B2 (en) | 1999-06-04 | 2000-06-02 | Stable biocidal compositions |
EP00931765A EP1182931B1 (en) | 1999-06-04 | 2000-06-02 | Stable biocidal compositions |
DE60025198T DE60025198D1 (en) | 1999-06-04 | 2000-06-02 | STABLE BIOZIDAL COMPOSITION |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ33613999A NZ336139A (en) | 1999-06-04 | 1999-06-04 | Pesticidal emulsion composition containing levamisole in the aqueous phase and an anthelmintic in the organic phase |
NZ336139 | 1999-06-04 | ||
NZ336213 | 1999-06-10 | ||
NZ33621399 | 1999-06-10 | ||
NZ33681499 | 1999-07-19 | ||
NZ336814 | 1999-07-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000074489A1 true WO2000074489A1 (en) | 2000-12-14 |
Family
ID=27353893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NZ2000/000087 WO2000074489A1 (en) | 1999-06-04 | 2000-06-02 | Stable biocidal compositions |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1182931B1 (en) |
AR (1) | AR035550A1 (en) |
AT (1) | ATE313952T1 (en) |
AU (2) | AU772988B2 (en) |
DE (1) | DE60025198D1 (en) |
WO (1) | WO2000074489A1 (en) |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1551390A1 (en) * | 2002-07-19 | 2005-07-13 | Ashmont Holdings Limited | Levamisole, avermectins or similar in pyrrolidone solvent |
EP1560572A1 (en) * | 2002-11-11 | 2005-08-10 | Schering-Plough PTY Ltd | Topical parasiticide formulations and methods of treatment |
WO2005074914A1 (en) * | 2004-02-03 | 2005-08-18 | Wyeth | Anthelmintic composition |
EP1581258A1 (en) * | 2002-12-12 | 2005-10-05 | Ashmont Holdings Limited | Pharmaceutical formulation and a method of making same |
EP1682125A1 (en) * | 2003-10-24 | 2006-07-26 | Agresearch Limited | Multiple active agents such as anthelmintics sustained release delivery |
WO2007057028A1 (en) * | 2005-11-18 | 2007-05-24 | Cheminova A/S | Oil-in-water formulation of avermectins |
JP2007514446A (en) * | 2003-12-19 | 2007-06-07 | メリアル リミテッド | Stabilized ivermectin feed premix formulation |
WO2007067470A2 (en) * | 2005-12-06 | 2007-06-14 | Wyeth | Benzimidazole non-aqueous compositions |
WO2007068073A3 (en) * | 2005-12-16 | 2007-08-16 | Ouro Fino Participacoes E Empr | Veterinarian composition comprising an organic salt of levamisole in combination with at least one avermectine and/or milbemycine |
WO2007119028A2 (en) * | 2006-04-19 | 2007-10-25 | Galderma S.A. | Composition including at least one aqueous phase and at least one fatty phase including ivermectin |
WO2008043973A1 (en) * | 2006-10-12 | 2008-04-17 | Galderma S.A. | Dermatological composition containing avermictin nanocapsules, method for preparing the same and uses thereof |
WO2008075984A2 (en) * | 2006-12-21 | 2008-06-26 | Bomac Research Limited | Tablet formulation including macrocyclic lactone and levamisole anthelmintic agents |
WO2010014015A1 (en) * | 2008-07-29 | 2010-02-04 | Bomac Research Limited | Tablet manufacturing method |
WO2010021555A1 (en) * | 2008-08-18 | 2010-02-25 | Schering-Plough Animal Health Limited | Anthelmintic compositions |
AU2007221747B2 (en) * | 2006-09-29 | 2010-05-20 | Bayer New Zealand Limited | Medicament |
WO2011027333A1 (en) * | 2009-09-07 | 2011-03-10 | Douglas Robert Cleverly | Granulated anthelmintic preparations and delivery systems |
WO2011048040A1 (en) * | 2009-10-19 | 2011-04-28 | Intervet International B.V. | Method and formulation for the control of parasites |
WO2011054068A1 (en) * | 2009-11-05 | 2011-05-12 | Ouro Fino Participações E Empreendimentos S/A | Pharmaceutical combinations, pharmaceutical compositions, medicament and method for the treatment of animals |
WO2011123773A1 (en) | 2010-04-02 | 2011-10-06 | Merial Limited | Parasiticidal compositions comprising multiple active agents, methods and uses thereof |
WO2011143479A1 (en) * | 2010-05-12 | 2011-11-17 | Merial Limited | Injectable parasiticidal formulations of levamisole and macrocyclic lactones |
WO2011161209A1 (en) | 2010-06-24 | 2011-12-29 | Intervet International B.V. | Injectable formulation of a macrocyclic lactone and levamisole |
WO2012177151A1 (en) | 2011-06-23 | 2012-12-27 | Bayer New Zealand Limited | Anti-parasitic composition comprising a macrocyclic lactone and levamisole and method of treatment of parasitic infestation |
WO2013043064A1 (en) * | 2011-09-23 | 2013-03-28 | Alleva Animal Health Limited | Veterinary anthelmintic delivery system |
WO2013030702A3 (en) * | 2011-08-16 | 2013-05-30 | Virbac Sa | Anthelmintic formulations and treatments |
AU2010101389B4 (en) * | 2010-12-08 | 2013-07-18 | Jurox Pty Ltd | Anthelmintic formulation |
WO2013165264A1 (en) * | 2012-05-01 | 2013-11-07 | Nexan Corporation Limited | Anthelmintic compositions |
AU2014201152B2 (en) * | 2006-12-21 | 2015-07-30 | Bayer New Zealand Limited | Tablet Formulation |
US9283176B2 (en) | 2008-10-08 | 2016-03-15 | Zoetis Services Llc | Benzimidazole anthelmintic compositions |
AU2016200283A1 (en) * | 2015-02-21 | 2016-09-08 | Al Hanbali, Othman Abdul Rahim DR | LEVIA: A New Injectable Parasiticidal Veterinary Formulation of Levamisole HCI and Ivermectin Solution |
AU2016201743B2 (en) * | 2010-05-12 | 2017-10-19 | Boehringer Ingelheim Animal Health USA Inc. | Injectable parasiticidal formulations of levamisole and macrocyclic lactones |
WO2018038623A1 (en) * | 2016-08-23 | 2018-03-01 | Donaghys Limited | Improvements in parasite treatments |
WO2019157241A1 (en) | 2018-02-08 | 2019-08-15 | Boehringer Ingelheim Animal Health USA Inc. | Parasiticidal compositions comprising eprinomectin and praziquantel, methods and uses thereof |
WO2020150032A1 (en) | 2019-01-16 | 2020-07-23 | Boehringer Ingelheim Animal Health USA Inc. | Topical compositions comprising a neonicotinoid and a macrocyclic lactone, methods and uses thereof |
WO2022103450A1 (en) * | 2020-11-10 | 2022-05-19 | Mountain Valley Md Inc | Water dissolvable macrocyclic lactone cyclodextrin complexes |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3980791A (en) * | 1973-06-22 | 1976-09-14 | Bayer Aktiengesellschaft | Tetramisole and levamisole pour-on anthelmintic compositions and methods of use |
JPS521046A (en) * | 1975-06-24 | 1977-01-06 | Oshio Sangyo Kk | Sterile packing method of foods |
US4278684A (en) * | 1980-06-17 | 1981-07-14 | Janssen Pharmaceutica N.V. | Non-toxic anthelminthic pour-on composition |
JPS5820622A (en) * | 1982-06-11 | 1983-02-07 | 押尾産業株式会社 | Method of packing food, etc. |
JPS5821615A (en) * | 1981-07-29 | 1983-02-08 | Fujisawa Pharmaceut Co Ltd | Preventive remedy for trematodiasis in grass-eating animals |
US4395407A (en) * | 1981-05-08 | 1983-07-26 | Janssen Pharmaceutica N.V. | Parasiticidal pour-on compositions |
EP0224249A1 (en) * | 1985-11-27 | 1987-06-03 | Syntex (U.S.A.) Inc. | Amorphous benzimidazole derivatives |
JPH04220398A (en) * | 1990-12-21 | 1992-08-11 | Fuji Photo Film Co Ltd | Lithographic wetting water composition and lithography |
JPH0717812A (en) * | 1993-07-05 | 1995-01-20 | Shinto Paint Co Ltd | Industrial mildewproofing composition |
CN1194832A (en) * | 1997-03-27 | 1998-10-07 | 王玉万 | Antiparasitic medicine containing avermectin/ivermectin for animals |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA842571B (en) * | 1983-04-07 | 1985-11-27 | Merck & Co Inc | Novel synergistic antiparasitic combinations |
GB8515459D0 (en) * | 1985-06-19 | 1985-07-24 | Young Robert Co Ltd | Parasitical compositions |
FR2584927B1 (en) * | 1985-07-17 | 1988-09-23 | Elf Aquitaine | LIQUID, STABLE, ANTHELMINTHIC AND FUNGICIDE COMPOSITION BASED ON BITHIONOL SULFOXIDE |
-
2000
- 2000-06-02 AR ARP000102753A patent/AR035550A1/en not_active Application Discontinuation
- 2000-06-02 AU AU49595/00A patent/AU772988B2/en not_active Expired
- 2000-06-02 WO PCT/NZ2000/000087 patent/WO2000074489A1/en active IP Right Grant
- 2000-06-02 AT AT00931765T patent/ATE313952T1/en not_active IP Right Cessation
- 2000-06-02 DE DE60025198T patent/DE60025198D1/en not_active Expired - Lifetime
- 2000-06-02 EP EP00931765A patent/EP1182931B1/en not_active Expired - Lifetime
-
2008
- 2008-12-18 AU AU2008260443A patent/AU2008260443A1/en not_active Abandoned
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3980791A (en) * | 1973-06-22 | 1976-09-14 | Bayer Aktiengesellschaft | Tetramisole and levamisole pour-on anthelmintic compositions and methods of use |
JPS521046A (en) * | 1975-06-24 | 1977-01-06 | Oshio Sangyo Kk | Sterile packing method of foods |
US4278684A (en) * | 1980-06-17 | 1981-07-14 | Janssen Pharmaceutica N.V. | Non-toxic anthelminthic pour-on composition |
US4395407A (en) * | 1981-05-08 | 1983-07-26 | Janssen Pharmaceutica N.V. | Parasiticidal pour-on compositions |
JPS5821615A (en) * | 1981-07-29 | 1983-02-08 | Fujisawa Pharmaceut Co Ltd | Preventive remedy for trematodiasis in grass-eating animals |
JPS5820622A (en) * | 1982-06-11 | 1983-02-07 | 押尾産業株式会社 | Method of packing food, etc. |
EP0224249A1 (en) * | 1985-11-27 | 1987-06-03 | Syntex (U.S.A.) Inc. | Amorphous benzimidazole derivatives |
JPH04220398A (en) * | 1990-12-21 | 1992-08-11 | Fuji Photo Film Co Ltd | Lithographic wetting water composition and lithography |
JPH0717812A (en) * | 1993-07-05 | 1995-01-20 | Shinto Paint Co Ltd | Industrial mildewproofing composition |
CN1194832A (en) * | 1997-03-27 | 1998-10-07 | 王玉万 | Antiparasitic medicine containing avermectin/ivermectin for animals |
Non-Patent Citations (6)
Title |
---|
DATABASE WPI Derwent World Patents Index; Class B02, AN 1983-26659K/11, XP002906244 * |
DATABASE WPI Derwent World Patents Index; Class B02, AN 1999-081974/08, XP002906247 * |
DATABASE WPI Derwent World Patents Index; Class B07, AN 1977-12122Y/07, XP002906243 * |
DATABASE WPI Derwent World Patents Index; Class C03, AN 1995-093720/13, XP002906246 * |
DATABASE WPI Derwent World Patents Index; Class P75, AN 1992-313277/38, XP002906242 * |
DATABASE WPI Derwent World Patents Index; Class Q31, AN 1983-26424K/11, XP002906245 * |
Cited By (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1551390A1 (en) * | 2002-07-19 | 2005-07-13 | Ashmont Holdings Limited | Levamisole, avermectins or similar in pyrrolidone solvent |
EP1551390A4 (en) * | 2002-07-19 | 2008-11-05 | Merial Ltd | Levamisole, avermectins or similar in pyrrolidone solvent |
JP4643990B2 (en) * | 2002-11-11 | 2011-03-02 | シェーリング−プラウ・リミテッド | Surface parasiticidal formulations and methods of treatment |
JP2006508108A (en) * | 2002-11-11 | 2006-03-09 | シェーリング−プラウ リミテッド | Surface parasiticidal formulations and methods of treatment |
JP2007008963A (en) * | 2002-11-11 | 2007-01-18 | Schering-Plough Ltd | Surface parasiticide formulation and method of treatment |
EP1560572A4 (en) * | 2002-11-11 | 2011-05-04 | Schering Plough Ltd | Topical parasiticide formulations and methods of treatment |
EP1560572A1 (en) * | 2002-11-11 | 2005-08-10 | Schering-Plough PTY Ltd | Topical parasiticide formulations and methods of treatment |
EP1581258A1 (en) * | 2002-12-12 | 2005-10-05 | Ashmont Holdings Limited | Pharmaceutical formulation and a method of making same |
EP1581258A4 (en) * | 2002-12-12 | 2011-06-15 | Merial Ltd | Pharmaceutical formulation and a method of making same |
EP1682125A1 (en) * | 2003-10-24 | 2006-07-26 | Agresearch Limited | Multiple active agents such as anthelmintics sustained release delivery |
EP1682125A4 (en) * | 2003-10-24 | 2007-09-19 | Agres Ltd | Multiple active agents such as anthelmintics sustained release delivery |
JP2007514446A (en) * | 2003-12-19 | 2007-06-07 | メリアル リミテッド | Stabilized ivermectin feed premix formulation |
AU2005210632B2 (en) * | 2004-02-03 | 2011-02-03 | Zoetis Services Llc | Anthelmintic composition |
WO2005074914A1 (en) * | 2004-02-03 | 2005-08-18 | Wyeth | Anthelmintic composition |
WO2007057028A1 (en) * | 2005-11-18 | 2007-05-24 | Cheminova A/S | Oil-in-water formulation of avermectins |
EA013798B1 (en) * | 2005-11-18 | 2010-06-30 | Кеминова А/С | Oil-in-water formulation of avermectins |
AU2006314902B2 (en) * | 2005-11-18 | 2010-12-16 | Cheminova A/S | Oil-in-water formulation of avermectins |
JP2009518400A (en) * | 2005-12-06 | 2009-05-07 | ワイス | Benzidiimidazole non-aqueous composition |
AU2006322120B2 (en) * | 2005-12-06 | 2012-07-26 | Zoetis Services Llc | Benzimidazole non-aqueous compositions |
US7687471B2 (en) | 2005-12-06 | 2010-03-30 | Wyeth Llc | Benzimidazole non-aqueous compositions |
WO2007067470A2 (en) * | 2005-12-06 | 2007-06-14 | Wyeth | Benzimidazole non-aqueous compositions |
WO2007067470A3 (en) * | 2005-12-06 | 2007-10-18 | Wyeth Corp | Benzimidazole non-aqueous compositions |
AU2006324315B8 (en) * | 2005-12-16 | 2013-02-21 | Npa - Nucleo De Pesquisas Aplicadas Ltda. | Veterinarian composition comprising an organic salt of levamisole in combination with at least one avermectine and/or milbemycine |
EP1968585A4 (en) * | 2005-12-16 | 2009-11-18 | Ouro Fino Participacoes E Empr | Veterinarian composition to control helminthes in bovines, swines, caprines, equines, ovines, canines and felines |
WO2007068073A3 (en) * | 2005-12-16 | 2007-08-16 | Ouro Fino Participacoes E Empr | Veterinarian composition comprising an organic salt of levamisole in combination with at least one avermectine and/or milbemycine |
EP1968585A2 (en) * | 2005-12-16 | 2008-09-17 | Ouro Fino Participacoes e Empreendimantos S/A | Veterinarian composition to control helminthes in bovines, swines, caprines, equines, ovines, canines and felines |
AU2006324315A8 (en) * | 2005-12-16 | 2013-02-21 | Npa - Nucleo De Pesquisas Aplicadas Ltda. | Veterinarian composition comprising an organic salt of levamisole in combination with at least one avermectine and/or milbemycine |
AU2006324315B2 (en) * | 2005-12-16 | 2012-10-25 | Npa - Nucleo De Pesquisas Aplicadas Ltda. | Veterinarian composition comprising an organic salt of levamisole in combination with at least one avermectine and/or milbemycine |
US8227427B2 (en) | 2005-12-16 | 2012-07-24 | NPA—Nucleo de Pesquisas Aplicadas Ltda. | Veterinarian composition comprising an organic salt of levamisole in combination with at least one avermectin and/or milbemycin |
EP2374449A3 (en) * | 2006-04-19 | 2012-02-29 | Galderma S.A. | Composition including at least one aqueous phase and at least one oil phase including ivermectin |
EP2374449A2 (en) * | 2006-04-19 | 2011-10-12 | Galderma S.A. | Composition including at least one aqueous phase and at least one oil phase including ivermectin |
US9592249B2 (en) | 2006-04-19 | 2017-03-14 | Galderma S.A. | Compositions comprising at least one aqueous phase and at least one fatty phase which comprises avermectin compounds |
WO2007119028A2 (en) * | 2006-04-19 | 2007-10-25 | Galderma S.A. | Composition including at least one aqueous phase and at least one fatty phase including ivermectin |
FR2900052A1 (en) * | 2006-04-19 | 2007-10-26 | Galderma Sa | COMPOSITION COMPRISING AT LEAST ONE AQUEOUS PHASE AND AT LEAST ONE FATTY PHASE COMPRISING IVERMECTIN |
US8362069B2 (en) | 2006-04-19 | 2013-01-29 | Galderma S.A. | Compositions comprising at least one aqueous phase and at least one fatty phase which comprises avermectin compounds |
WO2007119028A3 (en) * | 2006-04-19 | 2008-04-03 | Galderma Sa | Composition including at least one aqueous phase and at least one fatty phase including ivermectin |
AU2007221747C1 (en) * | 2006-09-29 | 2014-02-27 | Bayer New Zealand Limited | Medicament |
AU2007221747B2 (en) * | 2006-09-29 | 2010-05-20 | Bayer New Zealand Limited | Medicament |
WO2008043973A1 (en) * | 2006-10-12 | 2008-04-17 | Galderma S.A. | Dermatological composition containing avermictin nanocapsules, method for preparing the same and uses thereof |
FR2907012A1 (en) * | 2006-10-12 | 2008-04-18 | Galderma Sa | DERMATOLOGICAL COMPOSITION COMPRISING AVERMECTIN NANOCAPSULES, PROCESS FOR PREPARING THE SAME AND USE THEREOF |
US8491928B2 (en) | 2006-10-12 | 2013-07-23 | Galderma S.A. | Dermatological compositions comprising avermectin nanocapsules |
EP2388009A1 (en) | 2006-10-12 | 2011-11-23 | Galderma S.A. | Dermatological composition containing avermictin nanocapsules, method for preparing the same and uses thereof |
US8309121B2 (en) | 2006-10-12 | 2012-11-13 | Galderma S.A. | Dermatological compositions comprising avermectin nanocapsules |
WO2008075984A2 (en) * | 2006-12-21 | 2008-06-26 | Bomac Research Limited | Tablet formulation including macrocyclic lactone and levamisole anthelmintic agents |
AU2014201152C1 (en) * | 2006-12-21 | 2017-01-12 | Bayer New Zealand Limited | Tablet Formulation |
WO2008075984A3 (en) * | 2006-12-21 | 2008-07-31 | Bomac Research Ltd | Tablet formulation including macrocyclic lactone and levamisole anthelmintic agents |
AU2014201152B2 (en) * | 2006-12-21 | 2015-07-30 | Bayer New Zealand Limited | Tablet Formulation |
WO2010014015A1 (en) * | 2008-07-29 | 2010-02-04 | Bomac Research Limited | Tablet manufacturing method |
WO2010021555A1 (en) * | 2008-08-18 | 2010-02-25 | Schering-Plough Animal Health Limited | Anthelmintic compositions |
AU2009283313C1 (en) * | 2008-08-18 | 2014-07-31 | Intervet Ineternational B.V. | Anthelmintic compositions |
AU2009283313B2 (en) * | 2008-08-18 | 2014-07-17 | Intervet Ineternational B.V. | Anthelmintic compositions |
US9283176B2 (en) | 2008-10-08 | 2016-03-15 | Zoetis Services Llc | Benzimidazole anthelmintic compositions |
AU2022200149B2 (en) * | 2009-09-07 | 2023-06-15 | Argenta Innovation Limited | Granulated anthelmintic preparations and delivery systems |
WO2011027333A1 (en) * | 2009-09-07 | 2011-03-10 | Douglas Robert Cleverly | Granulated anthelmintic preparations and delivery systems |
US11253593B2 (en) | 2009-09-07 | 2022-02-22 | Argenta Innovation Limited | Granulated anthelmintic preparations and delivery systems |
AU2020202781B2 (en) * | 2009-09-07 | 2021-05-13 | Argenta Innovation Limited | Granulated anthelmintic preparations and delivery systems |
WO2011048040A1 (en) * | 2009-10-19 | 2011-04-28 | Intervet International B.V. | Method and formulation for the control of parasites |
WO2011054068A1 (en) * | 2009-11-05 | 2011-05-12 | Ouro Fino Participações E Empreendimentos S/A | Pharmaceutical combinations, pharmaceutical compositions, medicament and method for the treatment of animals |
EP3175711A1 (en) | 2010-04-02 | 2017-06-07 | Merial, Inc. | Parasiticidal compositions comprising multiple active agents, methods and uses thereof |
WO2011123773A1 (en) | 2010-04-02 | 2011-10-06 | Merial Limited | Parasiticidal compositions comprising multiple active agents, methods and uses thereof |
AU2016201743B2 (en) * | 2010-05-12 | 2017-10-19 | Boehringer Ingelheim Animal Health USA Inc. | Injectable parasiticidal formulations of levamisole and macrocyclic lactones |
AU2017279645B2 (en) * | 2010-05-12 | 2019-09-19 | Boehringer Ingelheim Animal Health USA Inc. | Injectable parasiticidal formulations of levamisole and macrocyclic lactones |
AU2011252987B2 (en) * | 2010-05-12 | 2013-05-02 | Boehringer Ingelheim Animal Health USA Inc. | Injectable parasiticidal formulations of levamisole and macrocyclic lactones |
WO2011143479A1 (en) * | 2010-05-12 | 2011-11-17 | Merial Limited | Injectable parasiticidal formulations of levamisole and macrocyclic lactones |
WO2011161209A1 (en) | 2010-06-24 | 2011-12-29 | Intervet International B.V. | Injectable formulation of a macrocyclic lactone and levamisole |
AU2010101389C4 (en) * | 2010-12-08 | 2017-03-02 | Jurox Pty Ltd | Anthelmintic formulation |
AU2010101389B4 (en) * | 2010-12-08 | 2013-07-18 | Jurox Pty Ltd | Anthelmintic formulation |
CN103717218A (en) * | 2011-06-23 | 2014-04-09 | 拜耳新西兰有限公司 | Anti-parasitic composition comprising a macrocyclic lactone and levamisole and method of treatment of parasitic infestation |
WO2012177151A1 (en) | 2011-06-23 | 2012-12-27 | Bayer New Zealand Limited | Anti-parasitic composition comprising a macrocyclic lactone and levamisole and method of treatment of parasitic infestation |
US9198430B2 (en) | 2011-06-23 | 2015-12-01 | Bayer New Zealand Limited | Anti-parasitic composition comprising a macrocyclic lactone and levamisole and method of treatment of parasitic infestation |
AU2012273538B2 (en) * | 2011-06-23 | 2015-11-19 | Elanco New Zealand | Anti-parasitic composition comprising a macrocyclic lactone and levamisole and method of treatment of parasitic infestation |
EP2723335A4 (en) * | 2011-06-23 | 2015-01-07 | Bayer New Zealand Ltd | Anti-parasitic composition comprising a macrocyclic lactone and levamisole and method of treatment of parasitic infestation |
JP2014517066A (en) * | 2011-06-23 | 2014-07-17 | バイエル・ニュージーランド・リミテッド | Antiparasitic compositions comprising macrocyclic lactones and levamisole, and methods of treating parasitic infections |
CN103717218B (en) * | 2011-06-23 | 2017-09-12 | 拜耳新西兰有限公司 | Anti-parasitic compositions comprising macrolide and levamisol and the method for treating parasitic infection |
EP2723335A1 (en) * | 2011-06-23 | 2014-04-30 | Bayer New Zealand Limited | Anti-parasitic composition comprising a macrocyclic lactone and levamisole and method of treatment of parasitic infestation |
WO2013030702A3 (en) * | 2011-08-16 | 2013-05-30 | Virbac Sa | Anthelmintic formulations and treatments |
EP2744495B1 (en) | 2011-08-16 | 2017-01-18 | Virbac | Anthelmintic formulations and treatments |
AU2012303747B2 (en) * | 2011-08-16 | 2017-07-06 | Virbac | Anthelmintic formulations and treatments |
WO2013043064A1 (en) * | 2011-09-23 | 2013-03-28 | Alleva Animal Health Limited | Veterinary anthelmintic delivery system |
AU2013257335B2 (en) * | 2012-05-01 | 2017-03-02 | Nexan Corporation Limited | Anthelmintic compositions |
WO2013165264A1 (en) * | 2012-05-01 | 2013-11-07 | Nexan Corporation Limited | Anthelmintic compositions |
AU2016200283A1 (en) * | 2015-02-21 | 2016-09-08 | Al Hanbali, Othman Abdul Rahim DR | LEVIA: A New Injectable Parasiticidal Veterinary Formulation of Levamisole HCI and Ivermectin Solution |
AU2016200283B2 (en) * | 2015-02-21 | 2016-10-13 | Al Hanbali, Othman Abdul Rahim DR | LEVIA: A New Injectable Parasiticidal Veterinary Formulation of Levamisole HCI and Ivermectin Solution |
WO2018038623A1 (en) * | 2016-08-23 | 2018-03-01 | Donaghys Limited | Improvements in parasite treatments |
WO2019157241A1 (en) | 2018-02-08 | 2019-08-15 | Boehringer Ingelheim Animal Health USA Inc. | Parasiticidal compositions comprising eprinomectin and praziquantel, methods and uses thereof |
WO2020150032A1 (en) | 2019-01-16 | 2020-07-23 | Boehringer Ingelheim Animal Health USA Inc. | Topical compositions comprising a neonicotinoid and a macrocyclic lactone, methods and uses thereof |
WO2022103450A1 (en) * | 2020-11-10 | 2022-05-19 | Mountain Valley Md Inc | Water dissolvable macrocyclic lactone cyclodextrin complexes |
Also Published As
Publication number | Publication date |
---|---|
ATE313952T1 (en) | 2006-01-15 |
AU2008260443A1 (en) | 2009-01-15 |
AU4959500A (en) | 2000-12-28 |
AU772988B2 (en) | 2004-05-13 |
EP1182931B1 (en) | 2005-12-28 |
AR035550A1 (en) | 2004-06-16 |
DE60025198D1 (en) | 2006-02-02 |
EP1182931A1 (en) | 2002-03-06 |
EP1182931A4 (en) | 2003-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1182931B1 (en) | Stable biocidal compositions | |
US5169846A (en) | Non-aqueous micellar solutions of anthelmintic benzimidazoles, closantel, or phenothiazine, and insect growth regulators | |
CN106132409B (en) | Stable veterinary anthelmintic formulations | |
IE69667B1 (en) | Formulations comprising praziquantel and another anthelmintic | |
JP2007008963A (en) | Surface parasiticide formulation and method of treatment | |
WO2010021555A1 (en) | Anthelmintic compositions | |
NZ515772A (en) | Pesticidal emulsion composition containing levamisole in the aqueous phase and an anthelmintic in the organic phase | |
NZ336139A (en) | Pesticidal emulsion composition containing levamisole in the aqueous phase and an anthelmintic in the organic phase | |
AU2002301375B2 (en) | Stable biocidal composition | |
JP6120834B2 (en) | Antiparasitic compositions comprising macrocyclic lactones and levamisole, and methods of treating parasitic infections | |
AU2003101020B4 (en) | Stable Biocidal Compositions | |
FR2609631A1 (en) | Stable liquid compositions based on biothionol | |
KR101233488B1 (en) | Anthelmintic formulations | |
AU2006249206A1 (en) | Stable biocidal compositions | |
JP2966530B2 (en) | Pouring preparations effective for controlling in vivo and extracorporeal parasites of constant temperature animals and methods of using the same | |
EP0209462A1 (en) | Liquid stable anthelmintic and fungicidal composition based on bithionol sulfoxide | |
NZ527961A (en) | Stable biocidal compositions | |
EP3393455B1 (en) | Injectable formulation of a macrocyclic lactone and levamisole | |
CN103108624B (en) | Show the non-water oiliness injectable formulation of antiseptic effect | |
Barron | Appendix II Formulary for Common Wildlife Species | |
AU2001235489A1 (en) | Veterinary compositions for the treatment of parasitic diseases | |
WO2003011214A2 (en) | Novel methods and formulations for administration of active agents | |
BR112016020896B1 (en) | STABLE VETERINARY ANTIHELMINTIC FORMULATIONS | |
AU2008201426A1 (en) | Anthelmintic compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 49595/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000931765 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09926696 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2000931765 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000931765 Country of ref document: EP |